Buying guide
Apple Watch vs Evie Ring (and EvieMED) in 2026
Comparing 2 humanoid robots across availability, pricing, capabilities, and verified deployments. Current as of 2026.
| Attribute | No image on file | No image on file |
|---|---|---|
| Manufacturer | Apple | Movano Health |
| Form factor | biometric | biometric |
| Maturity | commercial | commercial |
| Availability | shipping-nowshipping | pausedpaused |
| Price | $399-$799 (actual sale price) | Not announced |
| Capability claims |
| — |
| Brain | — | — |
| Verified deployments | 1Apple | 1Movano Health |
| Privacy practices | 13cloud-upload, third-party-sharing, location-tracking, on-device-processing, training-data-use, data-sale, data-retention, biometric-storage, data-deletion-control, data-sale, data-deletion-control, data-retention, biometric-storage | — |
| Sources on file | 26 | 8 |
Editorial summaries
Apple Watch
The Apple Watch (current Series 11 and Ultra 3, September 2025; Series 9/10 and Ultra 2 supported) is a biometric-primary smartwatch and the canonical reference of the biometric cohort, with the broadest FDA-cleared portfolio: ECG and AFib/irregular-rhythm notifications (De Novo 2018), sleep-apnea notifications (2024), and hypertension notifications (2025), plus fall and crash detection and the Vitals app. Its sensors (optical PPG, electrical ECG, temperature, accelerometer/gyro, blood-oxygen) need no subscription for the FDA-cleared medical features. Pricing anchors at about $399 for the Series base (aluminum, GPS), with the Ultra around $799 and the SE around $249 (the SE lacks ECG). A within-entity verified-vs-claimed exemplar: blood-oxygen was disabled in the US in January 2024 over the Masimo ITC ruling and re-enabled in August 2025 via a paired-iPhone calculation redesign. DEPLOY holds the claims to the specific cleared indications: these are cleared features with defined scope, not a general cardiac or sleep diagnostic.
Evie Ring (and EvieMED)
Movano Health's Evie Ring is a women's-health-focused smart ring (menstrual-cycle tracking, sleep, energy, heart rate, SpO2, and mood and goal trends; general-wellness, not a diagnostic) and the lifecycle-state-paused archetype of DEPLOY's biometric ring sub-cohort. The verified-vs-claimed distinction is critical: Evie Ring sales are PAUSED, not discontinued. Following Movano Health's Corvex reverse merger (closed March 19, 2026), an AI-infrastructure pivot, and a 1-for-10 reverse split, the company paused Evie Ring sales while a divestiture of its EvieMED clinical line is pending. EvieMED (the B2B/clinical variant) is an FDA 510(k)-cleared pulse oximeter and heart-rate device (December 2, 2024) for clinical trials, remote patient monitoring, and payors and pharma. DEPLOY records the consumer Evie Ring at paused availability with no current retail price. Aggregators routinely flatten this as 'Movano discontinued the Evie Ring'; the accurate state is sales-paused amid a corporate pivot, with the EvieMED divestiture pending (an intention where not yet closed). Movano Health trades as NASDAQ: MOVE (CEO John Mastrototaro).
Machine-readable: this page as markdown.